![Sanjay K. Kakkar](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sanjay K. Kakkar
Vorstandsvorsitzender bei Tranquis Therapeutics, Inc.
Aktive Positionen von Sanjay K. Kakkar
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Tranquis Therapeutics, Inc.
![]() Tranquis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tranquis Therapeutics, Inc. discovers and develops novel immuno-therapeutics for neurological diseases. It offers treatment for central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson 's disease, Alzheimer?s Disease, and age-related neuropathology. The company was founded by Chih-Ping Liu and Khoa D. Nguyen in June 2016 and is headquartered in Menlo Park, CA. | Vorstandsvorsitzender | 01.01.2018 | - |
Präsident | 01.01.2018 | - |
Karriereverlauf von Sanjay K. Kakkar
Ehemalige bekannte Positionen von Sanjay K. Kakkar
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Trigen Holdings AG
![]() Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | Präsident | 01.01.1997 | 15.12.2009 |
Peptilogics, Inc.
![]() Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | Direktor/Vorstandsmitglied | - | - |
Vorstandsvorsitzender | - | - | |
Armetheon, Inc.
![]() Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA. | Vorstandsvorsitzender | 03.06.2015 | - |
Pharmacia, Inc. | Corporate Officer/Principal | 01.01.1994 | - |
Novartis Corp.
![]() Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - | - |
Ausbildung von Sanjay K. Kakkar
Harvard University | Graduate Degree |
King's College London | Doctorate Degree |
Imperial College London | Graduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Vereinigtes Königreich | 3 |
Deutschland | 2 |
Operativ
Chief Executive Officer | 3 |
President | 2 |
Graduate Degree | 2 |
Sektoral
Health Technology | 4 |
Consumer Services | 4 |
Commercial Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Trigen Holdings AG
![]() Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | Commercial Services |
Novartis Corp.
![]() Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
Pharmacia, Inc. | |
Armetheon, Inc.
![]() Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA. | Health Technology |
Peptilogics, Inc.
![]() Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | Commercial Services |
Tranquis Therapeutics, Inc.
![]() Tranquis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tranquis Therapeutics, Inc. discovers and develops novel immuno-therapeutics for neurological diseases. It offers treatment for central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson 's disease, Alzheimer?s Disease, and age-related neuropathology. The company was founded by Chih-Ping Liu and Khoa D. Nguyen in June 2016 and is headquartered in Menlo Park, CA. | Health Technology |
- Börse
- Insiders
- Sanjay K. Kakkar
- Erfahrung